A kick-start for CLC antiporters' pharmacology.
Despite the role of chloride channels and anion/proton antiporters of the CLC protein family in physiological processes and different genetic diseases, their pharmacology has been under-developed. In this issue of Chemistry & Biology, Howery et al. report the synthesis of 4'-octanamidostilbene-2,2'-disulfonate, the first high-affinity inhibitor of a CLC antiporter, a critical step toward reviving the CLC pharmacology.